My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:ONNVF)

1.100 -0.220 (-16.67%)
Streaming Delayed Price Updated: 9:30 AM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ONNVF

< Previous 1 2 Next >
Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology
Via ACCESS Newswire
Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board
Via ACCESS Newswire
Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
Via ACCESS Newswire
Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care
Via ACCESS Newswire
Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board
Via ACCESS Newswire
Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised
Via ACCESS Newswire
Onco-Innovations Announces Closing of Private Placement
Via ACCESS Newswire
Onco-Innovations Advances Progress Towards First-in-Human Trial with Avance Clinical Start-Up Agreement
Via ACCESS Newswire
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Reduce development timelines and costs, while improving access to life-saving treatments 
From OneMedNet Corporation
Via GlobeNewswire
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Via ACCESS Newswire
Onco-Innovations Announces Private Placement
Via ACCESS Newswire
Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board
Via ACCESS Newswire
Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
Via ACCESS Newswire
Onco-Innovations Strengthens Clinical Leadership with Appointment of Dr. Islam Mohamed as Advisory Board Chair
Via ACCESS Newswire
Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials
Via ACCESS Newswire
Onco-Innovations CEO Highlights Strategic Milestones and R&D Progress in Special Investors' Conference Call
Via ACCESS Newswire
Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium
Via ACCESS Newswire
Onco-Innovations' CEO to Host Special Investors' Conference Call on Wednesday, July 2, 2025
Via ACCESS Newswire
Inka Health Co-Founders Publish New Study Advancing Real-World Applicability of Lung Cancer Clinical Trial Outcomes
Via ACCESS Newswire
Onco-Innovations Engages the University of Alberta and Cross Cancer Institute to Expand PNKP Inhibitor Research into Hard-to-Treat Cancers
Via ACCESS Newswire
Onco-Innovations' Inka Health to Launch Global AI-Oncology Consortium to Advance Predictive Cancer Research
Via ACCESS Newswire
Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
Via ACCESS Newswire
Onco-Innovations Extends Marketing Program
Via ACCESS Newswire
Onco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision Oncology
Via ACCESS Newswire
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
Via ACCESS Newswire
Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science
Via ACCESS Newswire
Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology
Via ACCESS Newswire
Onco-Innovations Announces Private Placement
Via ACCESS Newswire
Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
Via ACCESS Newswire
Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025
Via ACCESS Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.